Ruizhi Zhao
Overview
Explore the profile of Ruizhi Zhao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Gan J, Han M, Wu Y, Liu L, Zhao Y, et al.
Int J Biol Macromol
. 2024 Oct;
282(Pt 1):136755.
PMID: 39442850
Three polysaccharides from Vinegar-baked Radix Bupleuri (VR) and their combined effects were studied. VRP3-3 was a branched polysaccharide with a molecular weight (Mw) of 16.05 kDa characterized by 1,5 linked-α-Araf,...
2.
Zhao Y, Wu Y, Fan D, Deng H, Liu L, Deng S, et al.
Exp Dermatol
. 2024 Oct;
33(10):e70003.
PMID: 39435748
Psoriasis is a chronic autoimmune disease with a long disease course and frequent relapse characteristics. It is now recognised to be associated with epidermal environments of inflammatory cytokines. However, its...
3.
Tang X, Liu L, Wu Y, Zhao Y, Lu C, Zhao R
Int J Biol Macromol
. 2024 Sep;
280(Pt 1):135667.
PMID: 39278435
Atractylodis Macrocephalae Rhizoma (AMR), an herb often found in compounded remedies for psoriasis, is rich in polysaccharides. However, the beneficial effects of AMR polysaccharides on psoriasis remain obscure. In this...
4.
Walsh J, Lin I, Zhao R, Shiff N, Morrison L, Emond B, et al.
Drugs Real World Outcomes
. 2024 Jul;
11(3):487-499.
PMID: 39083163
Background: Treatment persistence among patients with psoriatic arthritis (PsA) is essential for achieving optimal treatment outcomes. Guselkumab, a fully human interleukin-23p19-subunit inhibitor, was approved by the United States (US) Food...
5.
Zhao R, Shao H, Shi G, Qiu Y, Tang T, Lin Y, et al.
J Natl Cancer Cent
. 2024 Jul;
4(1):86-92.
PMID: 39036380
Background: Approximately 10%-30% of patients with Hodgkin's lymphoma (HL) experience relapse or refractory (R/R) disease after first-line standard therapy. Brentuximab vedotin (BV) and immune checkpoint inhibitors (ICIs) have important roles...
6.
Liang M, Wu Y, Sun J, Zhao Y, Liu L, Zhao R, et al.
ACS Omega
. 2024 Apr;
9(16):18375-18384.
PMID: 38680328
Oxaliplatin (OXA) is recognized as a first-line drug for gastric cancer. However, low accumulation of the OXA in the target site and the development of drug resistance directly led to...
7.
Liu L, Zhang H, Tang X, Zhang M, Wu Y, Zhao Y, et al.
Int Immunopharmacol
. 2024 Apr;
133:112082.
PMID: 38652958
Psoriasis is an incurable immune-mediated disease affecting the skin or the joints. There are continuing studies on drugs for psoriasis prevention and treatment. This research found that Geniposide (GE) significantly...
8.
Zhdanava M, Kachroo S, Shah A, Ding Z, Lefebvre P, Zhao R, et al.
Patient Prefer Adherence
. 2024 Apr;
18:809-820.
PMID: 38617809
Purpose: To describe real-world persistence in bio-naïve and bio-experienced adults with ulcerative colitis (UC) treated with ustekinumab, a recently approved anti-interleukin 12/23 antibody, or adalimumab, an anti-TNF biologic. Methods: This...
9.
Zhao Y, Li P, Wang X, Wu Y, Liu L, Zhao R
Int J Biol Macromol
. 2024 Mar;
266(Pt 1):131096.
PMID: 38522695
Polysaccharides of vinegar-baked Radix Bupleuri (VBCP) have been reported to exhibit liver-targeting and immunomodulatory activities through oral administration, but the absorption behavior and mechanism of VBCPs have not been extensively...
10.
Wu Y, Liu L, Zhao Y, Li X, Hu J, Li H, et al.
J Ethnopharmacol
. 2024 Feb;
326:117923.
PMID: 38367929
Ethnopharmacological Relevance: Xiaoyaosan (XYS) is a traditional prescription for the treatment of liver depression and qi stagnation, and pharmacological studies have shown that XYS has great potential to reverse depression....